Kyntra Bio, Inc. (KYNB)
| Market Cap | 21.70M -51.1% |
| Revenue (ttm) | 4.62M -37.2% |
| Net Income | 183.19M |
| EPS | 45.27 |
| Shares Out | 4.05M |
| PE Ratio | 0.12 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,168 |
| Open | 5.50 |
| Previous Close | 5.57 |
| Day's Range | 5.34 - 5.73 |
| 52-Week Range | 5.34 - 11.65 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 38.50 (+618.28%) |
| Est. Earnings | Nov 9, 2026 |
About KYNB
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for KYNB stock is "Buy." The 12-month stock price target is $38.5, which is an increase of 618.28% from the latest price.
News
Kyntra Bio initiated with a Buy at Maxim on mCRPC potential
As previously reported, Maxim initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $35 price target Kyntra has “traversed a challenging period since its FibroGen days,” refining its…
Kyntra Bio initiated with a Buy at Maxim
Maxim analyst Michael Okunewitch initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $35 price target
Kyntra Bio appoints Singer to its board of directors
Kyntra Bio (KYNB) announced the appointment of Andrew Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The…
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of t...
Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential
As previously reported, Lake Street analyst Daniel Brims initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $41 price target Kyntra is developing drugs for solid and hematological…
Kyntra Bio initiated with a Buy at Lake Street
Lake Street initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $41 price target
Kyntra Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Kyntra Bio, rebranded from FibroGen, is advancing two key programs: a phase II trial for FG-3246 in mCRPC with interim results expected Q4 2024, and a phase III trial for roxadustat in lower risk MDS, also set to begin Q4 2024. Both programs target significant unmet needs and large markets.
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company's management will be attending and presenting at the H.C. Wainwright 28th Annual Global Inv...
Kyntra Bio cuts max royalty cap to $65M from $125M, pays $42.6M upfront
Kyntra Bio (KYNB) announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, materially reducing its payment obligations under the agree...
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoeb...
Kyntra Bio reports Q2 EPS $2.96, consensus ($3.18)
“We continue to make progress across our oncology and rare disease portfolio and remain laser-focused on advancing toward our goal of initiating a pivotal Phase 3 trial of roxadustat in…
Kyntra Bio Earnings Call Transcript: Q2 2026
Clinical programs for FG-3246 in mCRPC and roxadustat in lower risk MDS advanced, with key trials on track and strong cash reserves supporting operations into 2028. Q2 2026 saw a return to net income and increased R&D investment.
Kyntra Bio Earnings release: Q2 2026
Kyntra Bio released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Kyntra Bio Quarterly report: Q2 2026
Kyntra Bio has published its Q2 2026 quarterly earnings report on August 13, 2026.
Kyntra Bio Slides: Q2 2026
Kyntra Bio has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.
Kyntra Bio initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Kyntra Bio (KYNB) with an Outperform rating and $35 price target citing “optimism” about lead programs FG-3246 and FG-3180 to address the persistent unmet need among…
Kyntra Bio Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification. All proposals passed with strong support, and final voting results will be filed with the SEC.
Kyntra Bio to present additional MATTERHORN trial data at EHA
Kyntra Bio (KYNB) announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndro...
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patient...
Kyntra Bio initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $30 price target The company has a first-in-class CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration...
Kyntra Bio Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue growth and reduced expenses, with key clinical programs advancing as planned. FG-3246/FG-3180 phase II trial is on track for interim analysis in Q4 2026, and roxadustat is set for phase III initiation in H2 2026. Cash runway extends into 2028.
Kyntra Bio Earnings release: Q1 2026
Kyntra Bio released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Kyntra Bio Slides: Q1 2026
Kyntra Bio has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Kyntra Bio Quarterly report: Q1 2026
Kyntra Bio has published its Q1 2026 quarterly earnings report on May 11, 2026.